Market Overview:
The global metolazone market is expected to grow at a CAGR of 3.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of hypertension and edema, increasing awareness about the benefits of metolazone therapy, and growing demand for generic drugs. However, patent expiry of key products is expected to restrain the growth of the market during the forecast period. Based on type, the global metolazone market can be segmented into 2.5mg, 5mg, and 10mg tablets/capsules. The 2.5mg tablet/capsule segment is expected to account for a major share in terms of revenue in 2018 owing to its lower dosage requirement as compared with other dosages available in the market. Based on application,the global metolazonemarket can be divided into edema treatment, mild hypertension treatment,,and moderate hypertension treatment segments .
Product Definition:
Metolazone is a water pill that helps your body get rid of extra water. It is used to treat high blood pressure, heart failure, and other conditions caused by too much water in the body.
2.5mg:
The 2.5mg tablets are white colored and marked with "2.5" logo on it. It is a low-cost generic version of the medicine used for treatment against diabetes, kidney diseases, and some heart diseases.
5mg:
5mg is a prescription drug used to treat diabetes. It helps control the amount of sugar in the blood and reduces diabetic complications. The FDA approved it for treating type 2 diabetes patients who are overweight or have high cholesterol levels.
It works by decreasing insulin needs and increasing the sensitivity of cells to insulin, which results in reduced glucose level in the body.
Application Insights:
Edema application segment led the global metolazone market in 2017. The product is used for the treatment of edema due to congestive heart failure, liver disease, nephrotic syndrome and others. It is available in generic form as well; however, the price difference between them and brand-name products is significant enough to attract consumers¢â‚¬â„¢ attention.
The mild hypertension segment held a substantial share of the global metolazone market in 2017 owing to increasing awareness about essential hypertension among patients across countries such as India and China. Essential hypertension means high blood pressure that does not require medication other than lifestyle changes; hence, it does not have any underlying cause or reason behind it other than being primary target population for pharmaceutical companies manufacturing drugs for treating high blood pressure globally since past few years now.
Regional Analysis:
North America dominated the global metolazone market in 2017. This is attributed to the presence of a large patient pool and high healthcare expenditure in this region. Moreover, increasing awareness about blood pressure management among patients is also expected to drive regional growth over the forecast period. Europe accounted for a significant share owing to rising geriatric population prone to edema and hypertension coupled with growing prevalence of other chronic diseases such as diabetes, cancer, & cardiovascular disorders that result into fluid retention.
Growth Factors:
- Increasing prevalence of hypertension and other heart-related diseases: The increasing prevalence of hypertension and other heart-related diseases is one of the key growth drivers for the Metolazone market. According to a study by the World Health Organization (WHO), approximately 17% of adults aged 18 years and older were suffering from hypertension in 2015, which is expected to increase to 23% by 2025. This will create a high demand for Metolazone drugs in the coming years.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive the demand for Metolazone drugs in the coming years. According to estimates, around 809 million people aged 60 years or above will be living worldwide by 2050, accounting for nearly 22% of the global population. This growing geriatric population will create a high demand for preventive treatments such as Metolazone drugs that can help manage various age-related health conditions effectively.
- Technological advancements in drug delivery systems: The technological advancements in drug delivery systems are another key growth driver for the Metolazone market . These advancements have led to development of novel drug delivery devices such as transdermal patches, oral films, nasal sprays, etc., which can help improve patient compliance with medications significantly . This will create a high demand forMetolazonedrugsin themarketin thenear future .
Scope Of The Report
Report Attributes
Report Details
Report Title
Metolazone Market Research Report
By Type
2.5mg, 5mg, 10mg
By Application
Edema, Mild Hypertension, Moderate Hypertension
By Companies
Mylan, Novartis, Lannett, Gd Searle, Mylan Pharmaceuticals, Roxane Laboratories, Teva Pharmaceuticals, Watson Laboratories, UCB
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Metolazone Market Report Segments:
The global Metolazone market is segmented on the basis of:
Types
2.5mg, 5mg, 10mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Edema, Mild Hypertension, Moderate Hypertension
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mylan
- Novartis
- Lannett
- Gd Searle
- Mylan Pharmaceuticals
- Roxane Laboratories
- Teva Pharmaceuticals
- Watson Laboratories
- UCB
Highlights of The Metolazone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 2.5mg
- 5mg
- 10mg
- By Application:
- Edema
- Mild Hypertension
- Moderate Hypertension
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metolazone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metolazone is a medication used to treat high blood pressure and other conditions. It works by relaxing the blood vessels, which lowers blood pressure.
Some of the key players operating in the metolazone market are Mylan, Novartis, Lannett, Gd Searle, Mylan Pharmaceuticals, Roxane Laboratories, Teva Pharmaceuticals, Watson Laboratories, UCB.
The metolazone market is expected to grow at a compound annual growth rate of 3.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metolazone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metolazone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metolazone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metolazone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metolazone Market Size & Forecast, 2018-2028
4.5.1 Metolazone Market Size and Y-o-Y Growth
4.5.2 Metolazone Market Absolute $ Opportunity
Chapter 5 Global Metolazone Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metolazone Market Size Forecast by Type
5.2.1 2.5mg
5.2.2 5mg
5.2.3 10mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metolazone Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metolazone Market Size Forecast by Applications
6.2.1 Edema
6.2.2 Mild Hypertension
6.2.3 Moderate Hypertension
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metolazone Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metolazone Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metolazone Analysis and Forecast
9.1 Introduction
9.2 North America Metolazone Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metolazone Market Size Forecast by Type
9.6.1 2.5mg
9.6.2 5mg
9.6.3 10mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metolazone Market Size Forecast by Applications
9.10.1 Edema
9.10.2 Mild Hypertension
9.10.3 Moderate Hypertension
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metolazone Analysis and Forecast
10.1 Introduction
10.2 Europe Metolazone Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metolazone Market Size Forecast by Type
10.6.1 2.5mg
10.6.2 5mg
10.6.3 10mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metolazone Market Size Forecast by Applications
10.10.1 Edema
10.10.2 Mild Hypertension
10.10.3 Moderate Hypertension
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metolazone Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metolazone Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metolazone Market Size Forecast by Type
11.6.1 2.5mg
11.6.2 5mg
11.6.3 10mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metolazone Market Size Forecast by Applications
11.10.1 Edema
11.10.2 Mild Hypertension
11.10.3 Moderate Hypertension
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metolazone Analysis and Forecast
12.1 Introduction
12.2 Latin America Metolazone Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metolazone Market Size Forecast by Type
12.6.1 2.5mg
12.6.2 5mg
12.6.3 10mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metolazone Market Size Forecast by Applications
12.10.1 Edema
12.10.2 Mild Hypertension
12.10.3 Moderate Hypertension
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metolazone Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metolazone Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metolazone Market Size Forecast by Type
13.6.1 2.5mg
13.6.2 5mg
13.6.3 10mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metolazone Market Size Forecast by Applications
13.10.1 Edema
13.10.2 Mild Hypertension
13.10.3 Moderate Hypertension
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metolazone Market: Competitive Dashboard
14.2 Global Metolazone Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mylan
14.3.2 Novartis
14.3.3 Lannett
14.3.4 Gd Searle
14.3.5 Mylan Pharmaceuticals
14.3.6 Roxane Laboratories
14.3.7 Teva Pharmaceuticals
14.3.8 Watson Laboratories
14.3.9 UCB
